Nuclear chemistry plays a central role in modern medicine, powering both the imaging scans that detect disease and the targeted therapies that treat it. Radioactive atoms, carefully chosen for their specific properties, are attached to biological molecules and introduced into the body, where they either emit signals a camera can capture or deliver radiation precise enough to destroy diseased cells while largely sparing healthy tissue. The global radiopharmaceutical market reflects how essential this field has become: valued at $7.51 billion in 2025 and projected to nearly double to $14.44 billion by 2034.
Diagnostic Imaging With Radioactive Tracers
The most widespread medical use of nuclear chemistry is diagnostic imaging. A small amount of a radioactive substance, called a radiotracer, is injected into the bloodstream (or sometimes swallowed or inhaled). The tracer travels through the body and concentrates in specific organs or tissues depending on its chemistry. As the radioactive atoms decay, they emit gamma rays that specialized cameras detect and convert into detailed images of what’s happening inside the body.
One isotope dominates this field. Technetium-99m is used in roughly 85% of all nuclear medicine procedures worldwide. It works so well because it emits gamma rays at an energy level ideal for imaging, and its six-hour half-life is long enough to complete a scan but short enough that radiation exposure stays low. Technetium-99m can be attached to a wide variety of carrier molecules, letting it target the heart, bones, kidneys, lungs, or brain depending on the specific compound used.
The other major imaging technique uses positron-emitting isotopes, most commonly fluorine-18, in PET scans. Fluorine-18 is attached to a sugar molecule that mimics glucose. Cancer cells burn through glucose far faster than normal cells, a quirk of tumor biology known as the Warburg effect. Once injected, the radioactive sugar floods into these high-metabolism cells and gets trapped inside them. The fluorine-18 then emits positrons that almost immediately collide with nearby electrons, producing pairs of gamma rays that fly off in exactly opposite directions. The PET scanner detects these paired signals and uses them to pinpoint where the tracer accumulated, revealing tumors, monitoring treatment response, and detecting recurrence.
How PET and SPECT Scans Differ
Nuclear medicine imaging splits into two main technologies: SPECT (single-photon emission computed tomography) and PET (positron emission tomography). Both create 3D images of activity inside the body, but they work differently and have distinct strengths.
SPECT cameras detect single gamma rays emitted directly from tracers like technetium-99m. They use physical collimators, essentially lead grids, to determine the direction each gamma ray came from. This filtering improves image accuracy but also blocks a large portion of the useful signal, which limits image quality. Typical SPECT resolution is around 10 to 14 mm, though newer collimator designs are pushing cardiac scan resolution down to 3 to 4 mm.
PET scanners detect the paired gamma rays produced when a positron meets an electron. Because the scanner only counts events where two photons arrive at opposite detectors within a few nanoseconds of each other, it doesn’t need physical collimators. This makes PET two to three orders of magnitude more sensitive than SPECT, with resolution typically around 5 to 7 mm. PET scans are particularly valuable for cancer staging, neurological conditions, and cardiac viability assessments.
Radiation Doses in Perspective
A common concern about nuclear medicine scans is radiation exposure. Most procedures deliver an effective dose between 0.3 and 20 millisieverts. For context, the average person absorbs about 3 millisieverts per year just from natural background radiation, including cosmic rays, radon gas, and naturally occurring radioactive elements in food and soil. A typical nuclear medicine scan, then, is comparable to somewhere between a few weeks and a few years of everyday background exposure. Diagnostic isotopes are specifically chosen for short half-lives so they clear the body quickly, minimizing the total radiation your tissues absorb.
Treating Thyroid Disease With Radioactive Iodine
The oldest and most established therapeutic use of nuclear chemistry targets the thyroid gland. The thyroid naturally absorbs iodine from the bloodstream to make hormones, concentrating it 20 to 40 times above the level found in blood plasma. In an overactive thyroid, that concentration can increase tenfold further. Radioactive iodine-131, taken as a simple oral dose, exploits this biology. It travels through the bloodstream, gets pulled into thyroid cells by the same transport system that collects normal iodine, and then destroys those cells from within using beta radiation.
For thyroid cancer patients who have already had surgery, iodine-131 is used to destroy any remaining thyroid tissue. Post-surgical ablation typically uses a moderate dose, while treatment of thyroid carcinoma itself uses higher doses. The beauty of this approach is its precision: because almost no other tissue in the body concentrates iodine the way the thyroid does, the radiation is overwhelmingly confined to the target.
Targeted Radiation for Advanced Cancers
The same principle behind radioactive iodine therapy, delivering radiation directly to cancer cells, has been extended to other cancers using more sophisticated targeting strategies. Instead of relying on a natural uptake mechanism like iodine absorption, researchers attach therapeutic isotopes to molecules that seek out specific proteins on the surface of cancer cells.
One of the most significant recent advances targets metastatic prostate cancer. A radioactive isotope called lutetium-177 is linked to a molecule that binds to a protein found in abundance on prostate cancer cells. In a meta-analysis of six randomized controlled trials involving over 2,100 patients with advanced prostate cancer that had stopped responding to hormone therapy, this treatment was roughly four times more likely to produce a significant drop in PSA levels (a key marker of prostate cancer activity) compared to standard care. It also reduced the risk of cancer progression by 43%. The treatment showed a safety profile comparable to standard therapies, with no significant increase in serious side effects.
Alpha Particles: A More Powerful Approach
Most established radiation therapies use beta-emitting isotopes, which release relatively light, fast-moving electrons that travel several millimeters through tissue. A newer approach uses alpha-emitting isotopes instead. Alpha particles are far heavier and deposit their energy over a very short distance, just 50 to 100 micrometers, roughly the width of a few cells. This concentrated energy is much more effective at breaking both strands of a cancer cell’s DNA simultaneously, which is far harder for the cell to repair than the single-strand breaks beta radiation typically causes.
Actinium-225 has emerged as a particularly promising alpha emitter because it doesn’t just release one alpha particle as it decays. It produces a cascade of four alpha particles and two beta particles through a chain of daughter isotopes, multiplying the destructive effect on targeted cancer cells. The short range of alpha particles also means surrounding healthy tissue receives very little radiation, potentially reducing side effects compared to therapies that use longer-range beta emitters. This approach is especially relevant for treating small clusters of cancer cells or micrometastases that have spread through the body.
Why Different Isotopes Suit Different Jobs
The choice between diagnostic and therapeutic isotopes comes down to two properties: the type of radiation emitted and how long the isotope lasts. Diagnostic isotopes need to emit gamma rays or positrons that cameras can detect from outside the body, and they need short half-lives so they clear quickly and keep radiation exposure minimal. Therapeutic isotopes need to emit beta or alpha particles that damage cells at close range, and they need longer half-lives, generally between 6 hours and 10 days, so they stay active long enough to accumulate in tumors and deliver a meaningful radiation dose.
This distinction also shapes an emerging concept in nuclear medicine called theranostics, where a diagnostic isotope and a therapeutic isotope are attached to the same targeting molecule. Doctors first scan the patient with the diagnostic version to confirm the cancer cells carry the right surface protein, then switch to the therapeutic version to treat it. The lutetium-177 prostate cancer therapy works exactly this way, paired with a diagnostic gallium-68 PET scan that identifies suitable patients before treatment begins.
How Medical Isotopes Are Produced
Medical isotopes don’t occur naturally in useful quantities. They’re manufactured using nuclear reactors, cyclotrons, or linear accelerators. Reactors produce isotopes by bombarding target materials with neutrons, which is the traditional method for generating molybdenum-99, the parent isotope that decays into technetium-99m. Cyclotrons, compact particle accelerators found in many hospitals and radiopharmacies, produce isotopes by firing protons or other charged particles at target materials. Fluorine-18 for PET scans, gallium-68, and several other diagnostic isotopes are made this way. Linear accelerators offer a third production route, capable of generating both PET isotopes and molybdenum-99 through different nuclear reactions.
Production logistics matter because many medical isotopes decay quickly. Fluorine-18 has a half-life of about two hours, meaning a PET tracer made at a cyclotron facility needs to reach the patient within a tight window. This is why cyclotrons are often located at or near the hospitals that use their products, and why supply chain reliability is a persistent concern in nuclear medicine.